The gift of life: A visual history of organ transplantation
Animal stories
Genetics
New in medicineFacebookTweetLink
Follow
EDITOR'S NOTE: Watch 'Dr. Sanjay Gupta Reports: Animal Pharm' on Sunday, May 18, at 8 p.m. ET/PT on CNN.
There were more than 48,000 organ transplants in the United States last year. They're commonplace now, but the practice was considered experimental only a half-century ago.
Until just the past few years, transplants almost always involved human organs. Now, early experiments in xenotransplantation — transplanting animal organs into humans — are creating potential pathways to save lives.
Here's a look back at how we got to this point.
Xenotransplantation, the practice of transplanting organs between species, is a concept that has been around for hundreds of years.
Early in the 20th century, Dr. Mathieu Jaboulay turned the idea into action with one of the first well-documented attempts to make an animal organ work for a human. In 1906 in Lyon, France, Jaboulay attached a pig kidney to a 48-year-old woman's elbow, choosing that spot because it was easy to access. Blood circulated through the kidney, and the kidney produced urine, something even some human donations in this period failed to do, studies show.
The pig kidney quickly failed, and the patient died soon after due to an infection.
'The lack of having ready access to human organs has always sort of been the holy grail, that you would have something in reserve that didn't require a human to die in order for another human to live,' said Dr. Jeffrey Stern, a senior member of the NYU Langone Transplant Institute's xenotransplantation team. 'Obviously, animals as that source is sort of an ideal version of that.'
In 1954, the world's first successful human organ transplant was performed by Dr. Joseph E. Murray at what's now called Brigham and Women's Hospital in Boston.
Murray took a kidney from 22-year-old Ronald Herrick and transplanted it into Richard Herrick, his twin brother. Because they were identical, Richard's immune system thought the new organ was its own, which prevented it from rejecting the foreign organ. Richard Herrick lived another eight years, and his organ donor brother had no harmful side effects.
'I think that really moved the field,' said Dr. Stefan Tullius, chief of the Division of Transplant Surgery at Brigham and Women's Hospital.
'What that did show is that if you have the right combination and relationship between donor and recipient, then you indeed can transplant an organ and that is going to work,' Tullius added.
Since immunosuppressive drugs were not yet available, transplant experiments seemed to work only with twins whose immune systems thought the foreign organ were their own.
'You still ran into all those issues for the next 30 years with the immune system,' said Stern, who is also an assistant professor in the Department of Surgery at NYU Grossman School of Medicine. 'Not everyone has an identical twin.'
In the 1960s, Murray demonstrated in several experiments with dogs that an organ transplant would be more successful if the recipient received drugs to suppress the immune system after the procedure, to lower the chances of rejection.
In April 1962, in a world first that built on what he learned from those experiments, Murphy transplanted a kidney from a deceased donor into an unrelated human who was treated with an immunosuppressant called azathioprine. The patient survived more than a year, and s survival time lengthened even further when doctors discovered that an immunosuppressant worked better if given along with the steroid prednisone.
In June 1963, one of Murray's research fellows, Belgian surgeon Dr. Guy Alexandre, performed the first transplant operation from a brain-dead donor, a controversial procedure at the time. Alexandre had been searching for a kidney for a patient with renal failure when a woman who had been in a car accident was brought in to his Hôpital Saint-Pierre in Brussels. Her heart was beating, but she showed no brain activity. Knowing that organs lost viability as soon as a patient's heart stopped, Alexandre got permission from his department chair to transplant the woman's kidney into his patient with renal failure. The recipient lived another 87 days.
Over the next couple of years, Alexandre secretly performed other kidney transplants using brain-dead donors to see if such an approach would lengthen survival time compared with transplants from donors whose hearts had stopped. He disclosed the experiments at a medical conference a couple years later, to mixed reactions.
It wasn't until 1968 that a Harvard Medical School committee published its recommendation that irreversible loss of brain function – once called 'irreversible coma' – would be a new criterion for death. Afterward, transplants involving brain-dead donors became more common, vastly expanding the pool of available organs.
'To come up with the definition of brain death as an alternative to cardiac death – so the discontinuation of circulation – was huge, because it allowed the procurement of organs,' Tullius said.
Transplant doctors started experimenting with kidneys because humans have two and can survive with only one. Patients also had the option of dialysis if the transplant failed. But the more the doctors learned, the more confident they became that they could transplant other organs.
By the late 1960s, they started to experiment with livers and pancreases, and in 1967, South African surgeon Dr. Christiaan Barnard of Groote Schuur Hospital in Cape Town performed the first heart transplant. He transplanted a 25-year-old's heart into a 53-year-old grocer who was dying from chronic heart disease. The grocer died 18 days later from a lung infection, but the heart continued to beat until his death.
Barnard's second heart transplant patient lived almost 19 months. His fifth and sixth patients lived for almost 13 and 24 years, respectively.
By the 1990s, immunosuppressants like cyclosporine and tacrolimus opened new possibilities for transplants of multiple tissues. In 1998, Dr. Jean-Michel Dubernard did the first surgical hand transplant in Lyon, France. In 2005, he and Dr. Bernard Devauchelle performed the first partial face transplant for Isabelle Dinoire, a woman who lost part of her face in a dog attack. In 2010, a Spanish team led by Dr. Juan Barret performed the first full-face transplant.
'There's the first 30 years of transplantation that everything was sort of experimental, right?' Stern said. 'It wasn't a commonplace endeavor that we do what we currently do, and it was a lot of trial and error and survival, and sort of the entire field of transplantation, I think, was very tenuous in that. It was adaptation and invention of new technologies that allowed transplantation to become commonplace.'
In 1984, Dr. Leonard Bailey tried to save the life of Stephanie Fae Beauclair at Loma Linda University in California. The child, who became known as Baby Fae, was born with a deadly heart condition, and Bailey, who had been experimenting with cross-species transplants in animals, got permission to transplant a baboon heart. Stephanie lived just 21 more days, but the case generated more awareness about the need for infant organ donations and the possibility of cross-species transplantation.
Eventually, scientists decided that primates, although evolutionarily the closest cousin to humans, weren't the best organ donors.
'Primates turned out to be too small, too expensive and too controversial,' said medical ethicist Dr. Art Caplan, who works with transplant cases at NYU. There was also a concern about infection. Non-human primates may carry a variety of pathogens that are not harmful to them but that can cause disease in humans, including Marburg virus and HIV.
Eventually, scientists realized that pigs would be a better option: They're anatomically similar to humans, they breed quickly, and there was a reduced risk of zoonotic disease.
Research in xenotransplantation stalled until the development of the gene editing tool CRISPR in the early 2000s. This Nobel-winning technology gave scientists the ability to edit the pig genome to make it more compatible with humans', including knocking out key sequences in pig DNA that would result in almost automatic organ rejection in people. Combining that with cloning techniques gave scientists a chance to maintain consistent genetics and produce universal pig donors.
'Cloning and to apply CRISPR, to have the opportunity of gene editing, is really allowing not only transplantation but is also relevant for other areas of medicine,' Tullius said. 'I would put those in the revolutionary category.'
Pig organs had been transplanted into non-human primates, but the real test came in September 2021, when a genetically engineered pig kidney was transplanted to a brain-dead patient at NYU Langone.
The kidney was attached to the blood vessels in the recipient's upper leg, outside the abdomen, for 54 hours while doctors studied how well it functioned. The organ seemed to function as well as a human kidney transplant, and the doctors did not see any signs of rejection.
'We learned more from that than anything else that we've done,' Dr. Robert Montgomery, one of the surgeons who performed the procedure, told CNN Chief Medical Correspondent Dr. Sanjay Gupta. 'It was really the basis of how we were able to figure out how to treat rejection in our living patients.'
'The family graciously approved donation of their loved one's body for this procedure. That extraordinary generosity paved the way for this major step forward in creating a sustainable supply of life-saving organs and hopefully ending the current paradigm that someone has to die for someone to live,' Montgomery said in a news release at the time.
On January 7, 2022, surgeons at the University of Maryland School of Medicine performed the first xenotransplant into a living person.
David Bennett, 57, could not walk and relied on an artificial lung and heart bypass machine to stay alive. He was too sick to qualify for a human heart but was able to undergo the experimental procedure under the US Food and Drug Administration's compassionate use pathway, which allows patients with no other alternatives to try experimental treatments.
He lived two additional months, having the chance to spend more time with his family and watch the Super Bowl.
'As with any first-in-the-world transplant surgery, this one led to valuable insights that will hopefully inform transplant surgeons to improve outcomes and potentially provide lifesaving benefits to future patients,' said his surgeon, Dr. Bartley Griffith.
Bennett was the first of a handful of compassionate use xenotransplant patients. But as researchers approach clinical trials, they hope they will have a better understanding of how successful the organs can be under more typical circumstances.
'The promise of xenotransplantation is the promise of hope for our patients. A hope for the future that for too long has been uncertain. It is hope turned to possibility turned to reality. Our patients can dream again about graduations, weddings … about life. Hope should not have to be rationed,' said Dr. Jayme Locke, a professor of surgery at NYU Langone.
'Multiple shots on goal' is how geneticist Dr. David Ayares describes United Therapeutics' approach to the future of organ transplantation.
This summer, the company will embark on the first FDA clinical trial of xenotransplantation.
'So instead of one-off compassionate use transplants that were very valuable in learning how to optimize and extend the survival of these patients, now we can go into a multicenter trial,' Ayares, president and chief scientific officer of Revivicor, a United Therapeutics subsidiary, told Gupta.
But that still won't be enough to solve the organ shortage completely, so United Therapeutics and others in the transplant community are continuing to think farther into the future. 'I think the next thing we're going to do is … create personalized organs where we don't have to use any immunosuppression,' Montgomery said of what he expects down the road.
This could mean using a pig's organ as scaffolding where scientists could seed human stem cells, or even 3D-printing organs.
'Then you have a designer organ for that person when they need it,' Montgomery said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
16 minutes ago
- Associated Press
Novo Nordisk advances early-stage obesity medication, amycretin, to phase 3 clinical development based on early-phase clinical trial results in people with obesity or excess weight, published in The Lancet
PLAINSBORO, N.J., June 20, 2025 /PRNewswire/ -- Today, results from two early-phase clinical trials evaluating Novo Nordisk's amycretin, an innovative investigational obesity treatment designed to target appetite regulation, were published in The Lancet.1 In a phase 1b/2a clinical trial of 125 adults with overweight or obesity, once-weekly subcutaneous amycretin appeared to be safe and tolerable in trial participants, who also achieved significantly greater weight loss across the full range of doses investigated versus placebo.1 A related phase 1 trial of once-daily oral amycretin in adults with obesity or overweight also showed that treatment was safe and tolerable with an observed reduction in body weight compared to placebo.2 No weight loss plateau was observed in either trial at the end of the respective treatment durations.1,2 Data on subcutaneous amycretin is scheduled to be presented on Sunday, June 22nd, during a late-breaking poster session at the American Diabetes Association's® (ADA) 85th Scientific Sessions.1 'We are pleased with the promising results of amycretin and the feedback from regulatory authorities and are excited to advance both subcutaneous and oral versions of this molecule into phase 3 development for weight management. At Novo Nordisk, we understand that addressing obesity is a complex challenge that many patients face. These results reflect our robust pipeline in obesity, our focus on progressing scientific innovation and expanding the range of options available to patients and healthcare professionals,' said Martin Holst Lange, executive vice president for Development at Novo Nordisk. 'We remain steadfast in our mission to discover and develop therapies that can have a meaningful impact in the lives of those affected by obesity.' Results from the phase 1b/2a trial of subcutaneous amycretin showed treatment-emergent adverse events (TEAEs) were mild or moderate in severity and increased in frequency in a dose-dependent manner. The most frequent reported TEAEs were gastrointestinal in nature. Compared to placebo, participants receiving amycretin observed greater weight loss across the full range of doses investigated.1 Subcutaneous amycretin at multiple doses demonstrated greater weight reduction than placebo at the end of the trial. Participants who received the highest doses (up to 60 mg) reported body weight reductions of up to 24.3% versus 1.1% with placebo after 36 weeks of treatment. Results from this first-in-human phase 1b/2a study support further investigation of potential weight-loss efficacy of amycretin. Results from the published phase 1 trial of oral amycretin showed that the most common TEAEs were related to gastrointestinal symptoms (mainly nausea and vomiting) and decreased appetite; these were most frequent for the higher doses. Trial participants receiving the study treatment demonstrated significantly greater weight loss across the full range of doses investigated versus the placebo group.2 Exploratory results showed participants taking 100 mg per day of oral amycretin achieved a mean weight loss of 13.1% versus 1.2% with placebo after 12 weeks.2 Based on these phase 1 results, longer evaluation with more participants is warranted to substantiate the full efficacy findings of oral amycretin on body weight reductions and changes in metabolic parameters. Novo Nordisk will advance both subcutaneous and oral amycretin formulations straight to phase 3 development for weight management based on these and other completed clinical studies, as well as feedback received from regulatory authorities. About amycretin Amycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide a treatment for adults with overweight or obesity and as a treatment for adults with type 2 diabetes. Amycretin is under investigation for oral and subcutaneous administration, and is not approved in the US for weight loss. About the phase 1b/2a subcutaneous amycretin trial The phase 1b/2a trial was a randomized, placebo-controlled, single-center, double-blinded study of 125 participants assessing the safety, tolerability, pharmacokinetics, and effects on body weight after subcutaneous administration of amycretin in people with overweight or obesity.1 Adults with a body mass index of 27-39.9kg/m2 and glycated hemoglobin (HbA1c) <6.5% were eligible for the trial.1 The trial was conducted in 5 parts: a single ascending dose (Part A) for determination of pharmacokinetics and starting dose for the first multiple dose cohort in which the safety and tolerability were explored using dose escalation until 36 weeks of total treatment duration (Part B).1 Lastly, in the multiple ascending dose – dose response parts, body weight loss was explored for up to 36 weeks of dosing by escalating to dose levels of 1.25 mg, 5 mg, and 20 mg, respectively, dosed for 12 weeks (Part E, D and C).1 About the phase 1 oral amycretin trial The phase 1 single-center, randomized, placebo-controlled study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses (Part A) and multiple ascending doses (Part B, 10 days of treatment; Part C/D, 12 weeks of treatment) of 144 adult participants with overweight or obesity.2 The primary endpoint was the number of treatment-emergent adverse events (TEAEs) observed in the trial. The trial evaluated the single-ascending dose and multiple ascending doses for oral amycretin, up to 2 times 50 mg, in people with overweight or obesity, with a total treatment duration of up to 12 weeks.2 About obesity Obesity is a serious chronic, progressive, and complex disease that requires long-term management.3-5 One key misunderstanding is that this is a disease of just lack of willpower, when in fact there is underlying biology that may impede people with obesity from losing weight and keeping it off.3,5 Obesity is influenced by a variety of factors, including genetics, social determinants of health, and the environment.6,7 The prevalence of overweight and obesity is a public health issue that has severe cost implications to healthcare systems.8,9 In the US, about 40% of adults live with obesity.10 About Novo Nordisk Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a US presence spanning 40 years, Novo Nordisk US is headquartered in New Jersey and employs over 10,000 people throughout the country across 12 manufacturing, R&D and corporate locations in eight states plus Washington DC. For more information, visit Facebook, Instagram, and X. Novo Nordisk is committed to the responsible use of our semaglutide-containing medicines which represent distinct products with different indications, dosages, prescribing information, titration schedules, and delivery forms. These products are not interchangeable and should not be used outside of their approved indications. Learn more at Contacts for further information References © 2025 Novo Nordisk All rights reserved. US25SEMO01477 June 2025 View original content to download multimedia: SOURCE NOVO NORDISK INC.
Associated Press
16 minutes ago
- Associated Press
MountBay Energy Unlocks Microbial Biofilm Technology to Revolutionize Battery Longevity
NEW YORK, June 21, 2025 (GLOBE NEWSWIRE) -- MountBay Energy has unveiled groundbreaking research on microbial biofilms that could redefine the future of grid-scale energy storage. The study, led by founder Vrushabhraj Tanawade, introduces a bio-integrated insulation method using thermophilic and mesophilic microbial consortia to regulate heat inside battery modules. The results are striking: up to a 22% reduction in internal temperature and a 30% improvement in carbon lifecycle efficiency. 'This innovation is about biology meeting infrastructure,' says Tanawade. 'We've discovered how nature's mechanisms can dramatically extend the life of our clean energy systems.' Unlike conventional synthetic cooling solutions, MountBay's microbial approach is circular, biodegradable, and scalable—opening up new frontiers for climate resilience and fire-risk reduction in hot environments. The research aligns perfectly with MountBay's mission to power the AI economy through clean, sustainable, and advanced infrastructure. It also positions the company as a frontrunner in biological material integration across the energy sector. Additionally, MountBay has released a preliminary transformative feasibility report for a Lunar Solar Belt—a continuous solar array on the Moon that can beam uninterrupted, clean energy back to Earth. The report outlines how in-situ resource utilization (ISRU), autonomous lunar robotics, and microwave power transmission could enable the construction of a moon-based solar plant by the 2030s. With an energy return on investment (EROI) of 8:1, the system offers a scalable, emission-free solution to humanity's growing power demands. 'This is not just an energy project—it's a civilization-scale investment in global stability,' said Tanawade. 'We believe the Moon should be a cooperative utility, not a geopolitical race.' MountBay is also proposing a new diplomatic framework—The Earth-Moon Energy Accord (EMEA)—to ensure equitable access, safety, and international cooperation. The concept directly supports MountBay's mission: to push the frontiers of clean power while securing energy independence for AI-driven economies. Tanawade is rallying governments, institutions, and innovators to join him. 'It's time for America to lead the most ambitious energy project in human history,' he said. Media Contact: Vrushabhraj Tanawade Founder @ MountBay Energy Contact : [email protected] Website: Linkedin: Linkedin - Vrushabhraj T Disclaimer: This press release is provided by MountBay Energy. The statements, views, and opinions expressed are solely those of the provider and do not necessarily reflect those of this media platform or its publisher. Any names or brands mentioned are used for identification purposes only and remain the property of their respective owners. No endorsement or guarantee is made regarding the accuracy, completeness, or reliability of the information presented. This material is for informational purposes only and does not constitute financial, legal, or professional advice. Readers are encouraged to conduct independent research and consult qualified professionals. The publisher is not liable for any losses, damages, or legal issues arising from the use or publication of this content. Photos accompanying this announcement are available at:
Associated Press
16 minutes ago
- Associated Press
Banyan & Bamboo Launches AI-Powered '365 Beauty Blueprint' for Personalized Aesthetic Wellness in Austin
Austin's most soulful med spa is now one of its smartest. Banyan & Bamboo Day Spa + Med Spa unveils the '365 Beauty Blueprint' - a regenerative aesthetic protocol blending advanced facial mapping with deeply personalized, year-round wellness planning. Austin, TX, Texas, United States, June 21, 2025 -- Women-Led Spa Debuts Year-Round Aesthetic Strategy Backed by AI Banyan & Bamboo Day Spa + Med Spa, a boutique, women-led studio in the heart of Austin, today announces the launch of its signature 365 Beauty Blueprint, a highly personalized treatment plan guided by advanced AI skin mapping. This milestone reflects the spa's commitment to natural, data-backed results in regenerative aesthetics, setting a new standard for long-term self-care. In a field often driven by fleeting trends and one-size-fits-all treatments, Banyan & Bamboo introduces a new kind of beauty planning - one rooted in personalization, cellular science, and soulful care. Banyan & Bamboo's AI skin analysis and 365-day treatment plan is one of the most personalized options for injectables and facial care in Austin. 'We don't believe in one-size-fits-all beauty,' says Jennifer Rushing, Owner and Founder. 'We co-create yearlong blueprints that support skin, confidence, and health from the inside out.' Precision Meets Personalization: The 365 Beauty Blueprint At the heart of the new offering is AI-powered skin analysis - a diagnostic tool that maps hydration, pigmentation, texture, sun damage and aging markers. These insights allow the team to design evolving treatment plans that respond to each client's changing skin needs. The 365 Beauty Blueprint integrates: Every service within the protocol is selected to support internal wellness and natural-looking refinement. Regenerative Aesthetics in a Spa-Like Setting Blending clinical innovation with spa-caliber care, Banyan & Bamboo offers a slower, deeper, and more restorative alternative to volume-focused chains. Each visit includes in-depth consultation, customized protocols, and education - empowering clients to feel confident, cared for, and in control of their treatment journey. 'Our clients aren't here for a quick fix,' says Lindsey R., Spa Manager and Guest Experience Coordinator. 'They come to us because we spend time, educate them, and offer treatments that support long-term beauty and wellness.' Shifting the Industry Toward Longevity and Intention Since opening its doors, Banyan & Bamboo has cultivated one of the most loyal client communities in Central Texas. With the 365 Beauty Blueprint, the studio deepens its philosophy: beauty is not a single service, it's a long-term relationship. From hormone-safe skincare to regenerative injectables, each blueprint is crafted with intention and backed by science. The result is an customized aesthetic plan that's as restorative as it is effective - one that meets modern clients where they are and grows with them. 'Austin deserves more than cookie-cutter med spas,' adds Rushing. 'Our goal is to bring intention, expertise, and a little bit of Austin soul into every appointment.' Award-Winning Service In addition to the launch of the 365 Beauty Blueprint, Banyan & Bamboo is also celebrating a recent recognition as the Best Day Spa + Med Spa in Austin of 2025 by the prestigious Evergreen Awards. This accolade highlights their exceptional contributions to the wellness and aesthetics industry, particularly their blend of clinical precision and personalized care. Known for offering a standout menu of evidence-based aesthetic and wellness services, the spa's commitment to the natural, sustainable approach to beauty is reflected in their award. Banyan & Bamboo's regenerative aesthetics, including neuromodulators, dermal fillers, biostimulants, and cutting-edge injectable wellness therapies, consistently deliver natural results, backed by advanced AI-powered skin analysis for hyper-customized facial treatment plans. This focus on personalized, regenerative aesthetics, combined with their holistic approach, has fostered loyalty and built lasting relationships with clients. Owner and Founder Jennifer Rushing's leadership and the spa's deep connection with their clients have played a pivotal role in the studio's success, creating an environment where beauty meets wellness in a thoughtful, intentional way. About Banyan & Bamboo Day Spa | Med Spa Banyan & Bamboo is a boutique day spa and med spa in Austin, TX, specializing in regenerative aesthetics and clinical wellness treatments. The women-led studio offers AI-driven skin analysis, facial balancing, PRF therapies, injectable wellness services, and customized treatment blueprints. Built on the belief that science and soul should coexist, the spa delivers natural-looking results that last - inside and out. Media Contact: Name: Jennifer Rushing Title: Owner & Founder Email: [email protected] Contact Info: Name: Jennifer Rushing Email: Send Email Organization: Banyan & Bamboo Website: Release ID: 89162872 Should any errors, concerns, or inconsistencies arise from the content provided in this press release that require attention or if a press release needs to be taken down, we kindly request that you immediately contact us at [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our efficient team will be at your disposal for timely assistance within 8 hours – taking necessary measures to rectify identified issues or providing guidance on the removal process. We prioritize delivering accurate and reliable information.
